KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 5

Country-based report: the safety of omalizumab treatment in pregnant patients with asthma

Sevim BAVBEK
Bilun GEMİCİOĞLU
Arzu YORGANCIOĞLU
Yavuz HAVLUCU
Gül KARAKAYA
Zeynep Ferhan ÖZŞEKER
Dane EDİGER
Arzu Didem YALÇIN
Levent ÖZDEMİR
Metin KEREN
İpek Kıvılcım OĞUZÜLGEN
Sayfa
2516–2523
Yayın Tarihi
2022-11-06
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Omalizumab treatment during pregnancy seems to be safe for both patients and their infants.Key words: Exacerbation, gestation, infant, omalizumab, pregnancy, prematurity

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: We aimed to report outcomes of pregnant patients with asthma under omalizumab treatment and their infants in our country.
📊
Temel Bulgular & Veri:Materials and methods: Patients with asthma who received omalizumab for at least 6 months and at least one dose during their pregnancy were retrospectively evaluated using a questionnaire regarding their disease and therapy and the health of their infants.
💡
Sonuç & Katkı:Conclusion: Omalizumab treatment during pregnancy seems to be safe for both patients and their infants.Key words: Exacerbation, gestation, infant, omalizumab, pregnancy, prematurity
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: We aimed to report outcomes of pregnant patients with asthma under omalizumab treatment and their infants in our country. Materials and methods: Patients with asthma who received omalizumab for at least 6 months and at least one dose during their pregnancy were retrospectively evaluated using a questionnaire regarding their disease and therapy and the health of their infants. Results: Twenty pregnant patients and their 23 infant’s data were analyzed. The mean delivery age was 31.8 ± 7.4 years. They received omalizumab for 28.9 ± 21.8 months. Eight (36.4%) patients showed exacerbation of the disease during pregnancy. Forced expiratory volume in 1 s (FEV1) and asthma control test (ACT) scores at the starting time of omalizumab administration, first month of the pregnancy, and after delivery were 71 ± 18%, 83.4 ± 10.5%, and 80.5 ± 13% (FEV1), and 11.9 ± 4.9, 20.2 ± 2.6, and 20.4 ± 2.2 (ACT), respectively. One patient gave birth to twin infants, two patients to two infants each in different years, and 17 to one infant each. Three (13%) infants had low birth weight and five (21.7%) were born prematurely. No congenital anomalies were detected. Seven (30.4%) infants presented atopic diseases during their life. Conclusion: Omalizumab treatment during pregnancy seems to be safe for both patients and their infants.Key words: Exacerbation, gestation, infant, omalizumab, pregnancy, prematurity

🔖

Bu Makaleye Atıf Yap

BAVBEK, S., GEMİCİOĞLU, B., YORGANCIOĞLU, A., HAVLUCU, Y., KARAKAYA, G., ÖZŞEKER, Z. F., EDİGER, D., YALÇIN, A. D., ÖZDEMİR, L., KEREN, M., OĞUZÜLGEN, İ. K. (2022). Country-based report: the safety of omalizumab treatment in pregnant patients with asthma. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 5, 2516–2523. https://ajindex.com/articles/609324

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Fergeson JE, Patel SS, Lockey RF. Acute asthma, prognosis, and treatment. Journal of Allergy and Clinical Immunology 2017
  2. 139 (2): 438-447. doi: 10.1016/j.jaci.2016.06.054 2. Yildiz F, Oguzulgen IK, Dursun B, Mungan D, Gemicioglu B et al. Turkish Thoracic Society asthma management and prevention guideline: key points. Tuberculosis and Thorax 2011
  3. doi: 10.5578/tt.2750 3. Maselli DJ, Adams SG, Peters JI, Levine SM. Management of asthma during pregnancy. Therapeutic Advances in Respiratory Disease 2013
  4. 7 (2): 87-100. doi: 10.1177/1753465812464287 4. Murphy VE. Managing asthma in pregnancy. Breathe 2015
  5. 11 (4): 258-267. doi: 10.1183/20734735.007915 5. Bonham CA, Patterson KC, Strek ME. Asthma outcomes and management during pregnancy. Chest 2018
  6. 153 (2): 515-527. doi: 10.1016/j.chest.2017.08.029 6. Namazy J, Cabana MD, Scheuerle AE, Thorp JM Jr, Chen H et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. Journal of Allergy and Clinical Immunology 2015
  7. 135 (2): 407-412. doi: 10.1016/j. jaci.2014.08.025 7. Pfaller B, Yepes-Nuñez JJ, Agache I, Akdis CA, Alsalamah M et al. Biologicals in atopic disease in pregnancy: an EAACI position paper. Allergy 2021
  8. 76 (1): 71-89. doi: 10.1111/ all.14282 8. Yorgancıoğlu A, Öner Erkekol F, Mungan D, Erdinç M, Gemicioğlu B et al. Long-term omalizumab treatment: a multicenter, real-life, 5-year trial. International Archives of Allergy and Immunology 2018
  9. 176 (3-4): 225-233. doi: 10.1159/000488349 9. Yilmaz I, Erkekol FO, Celen S, Karaca MZ, Aydin Ö et al. Does drug compliance change in asthmatic patients during pregnancy. Multidisciplinary Respiratory Medicine 2013
  10. 8 (1): 38. doi: 10.1186/2049-6958-8-38 10. Mendola P, Wallace M, Hwang BS, Liu D, Robledo C et al. Preterm birth and air pollution: Critical windows of exposure for women with asthma. Journal of Allergy and Clinical Immunology 2016
  11. 138 (2): 432-440.e5. doi: 10.1016/j. jaci.2015.12.1309 11. Azad MB, Moyce BL, Guillemette L, Pascoe CD, Wicklow B et al. Diabetes in pregnancy and lung health in offspring: developmental origins of respiratory disease. Paediatric Respiratory Reviews 2017
  12. doi: 10.1016/j. prrv.2016.08.007 12. Schatz M, Dombrowski M, Wise R, Thom E, Landon M et al. Asthma morbidity during pregnancy can be predicted by severity classification. Journal of Allergy and Clinical Immunology 2003
  13. 283–288. doi: 10.1067/mai.2003.1516 13. Murphy V, Gibson P. Asthma in pregnancy. Clinical